Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07105722) titled 'A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age' on Aug. 4.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Investigator, Outcomes Assessor).
Primary Sponsor: GlaxoSmithKline
Condition:
Pneumonia, Bacterial
Intervention:
Biological: Pn-MAPS30plus
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: August 12, 2025
Target Sample Size: 120
Countries of Recruitment:
Australia
To know more, ...